139 related articles for article (PubMed ID: 25460504)
1. Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle.
Pretto F; Ghilardi C; Moschetta M; Bassi A; Rovida A; Scarlato V; Talamini L; Fiordaliso F; Bisighini C; Damia G; Bani MR; Piccirillo R; Giavazzi R
Oncotarget; 2015 Feb; 6(5):3043-54. PubMed ID: 25460504
[TBL] [Abstract][Full Text] [Related]
2. Adrenomedullin blockade suppresses sunitinib-resistant renal cell carcinoma growth by targeting the ERK/MAPK pathway.
Gao Y; Li J; Qiao N; Meng Q; Zhang M; Wang X; Jia J; Yang S; Qu C; Li W; Wang D
Oncotarget; 2016 Sep; 7(39):63374-63387. PubMed ID: 27556517
[TBL] [Abstract][Full Text] [Related]
3. Small-Molecule Chemical Knockdown of MuRF1 in Melanoma Bearing Mice Attenuates Tumor Cachexia Associated Myopathy.
Adams V; Gußen V; Zozulya S; Cruz A; Moriscot A; Linke A; Labeit S
Cells; 2020 Oct; 9(10):. PubMed ID: 33050629
[No Abstract] [Full Text] [Related]
4. Anti-Vascular Endothelial Growth Factor C Antibodies Efficiently Inhibit the Growth of Experimental Clear Cell Renal Cell Carcinomas.
Dumond A; Montemagno C; Vial V; Grépin R; Pagès G
Cells; 2021 May; 10(5):. PubMed ID: 34067671
[TBL] [Abstract][Full Text] [Related]
5. Ursolic acid alleviates cancer cachexia by inhibiting STAT3 signaling pathways in C2C12 myotube and CT26 tumor-bearing mouse model.
Chen L; Chen Y; Wang M; Lai L; Zheng L; Lu H
Eur J Pharmacol; 2024 Apr; 969():176429. PubMed ID: 38423241
[TBL] [Abstract][Full Text] [Related]
6. Distinct behaviour of sorafenib in experimental cachexia-inducing tumours: the role of STAT3.
Toledo M; Penna F; Busquets S; López-Soriano FJ; Argilés JM
PLoS One; 2014; 9(12):e113931. PubMed ID: 25436606
[TBL] [Abstract][Full Text] [Related]
7. Myostatin deficiency not only prevents muscle wasting but also improves survival in septic mice.
Kobayashi M; Kasamatsu S; Shinozaki S; Yasuhara S; Kaneki M
Am J Physiol Endocrinol Metab; 2021 Jan; 320(1):E150-E159. PubMed ID: 33284091
[TBL] [Abstract][Full Text] [Related]
8. Enhanced synergy of pacritinib with temsirolimus and sunitinib in preclinical renal cell carcinoma model by targeting JAK2/STAT pathway.
Mao F; Gao L; Liu L; Tang Y
J Chemother; 2024 May; 36(3):238-248. PubMed ID: 37916436
[TBL] [Abstract][Full Text] [Related]
9. STAT3 in the systemic inflammation of cancer cachexia.
Zimmers TA; Fishel ML; Bonetto A
Semin Cell Dev Biol; 2016 Jun; 54():28-41. PubMed ID: 26860754
[TBL] [Abstract][Full Text] [Related]
10. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products.
Acharyya S; Ladner KJ; Nelsen LL; Damrauer J; Reiser PJ; Swoap S; Guttridge DC
J Clin Invest; 2004 Aug; 114(3):370-8. PubMed ID: 15286803
[TBL] [Abstract][Full Text] [Related]
11. Anti-cachectic effect of FK317, a novel anti-cancer agent, in colon26 and LX-1 models in mice.
Naoe Y; Kawamura I; Inami M; Matsumoto S; Nishigaki F; Tsujimoto S; Manda T; Shimomura K
Jpn J Cancer Res; 1998 Dec; 89(12):1318-25. PubMed ID: 10081493
[TBL] [Abstract][Full Text] [Related]
12. Administration of adiponectin receptor agonist AdipoRon relieves cancer cachexia by mitigating inflammation in tumour-bearing mice.
Massart IS; Kouakou AN; Pelet N; Lause P; Schakman O; Loumaye A; Abou-Samra M; Deldicque L; Bindels LB; Brichard SM; Thissen JP
J Cachexia Sarcopenia Muscle; 2024 Apr; ():. PubMed ID: 38572511
[TBL] [Abstract][Full Text] [Related]
13. Modelling three-dimensional cancer-associated cachexia and therapy: The molecular basis and therapeutic potential of interleukin-6 transignalling blockade.
Cosentino M; Forcina L; Zouhair M; Apa L; Genovese D; Boccia C; Rizzuto E; Musarò A
J Cachexia Sarcopenia Muscle; 2023 Dec; 14(6):2550-2568. PubMed ID: 37727078
[TBL] [Abstract][Full Text] [Related]
14. YB-1 suppression induces STAT3 proteolysis and sensitizes renal cancer to interferon-α.
Takeuchi A; Shiota M; Tatsugami K; Yokomizo A; Kuroiwa K; Dejima T; Tanaka S; Itsumi M; Eto M; Naito S
Cancer Immunol Immunother; 2013 Mar; 62(3):517-27. PubMed ID: 23052245
[TBL] [Abstract][Full Text] [Related]
15. A novel transplantable model of lung cancer-associated tissue loss and disrupted muscle regeneration.
Arneson-Wissink PC; Ducharme AM; Doles JD
Skelet Muscle; 2020 Mar; 10(1):6. PubMed ID: 32151276
[TBL] [Abstract][Full Text] [Related]
16. Sex differences in skeletal muscle alterations in a model of colorectal cancer.
Greenman AC; Albrecht DM; Halberg RB; Diffee GM
Physiol Rep; 2020 Mar; 8(5):e14391. PubMed ID: 32170841
[TBL] [Abstract][Full Text] [Related]
17. Fish Oil, Se Yeast, and Micronutrient-Enriched Nutrition as Adjuvant Treatment during Target Therapy in a Murine Model of Lung Cancer.
Wang H; Hsia S; Wu TH; Wu CJ
Mar Drugs; 2021 May; 19(5):. PubMed ID: 34064322
[TBL] [Abstract][Full Text] [Related]
18. Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor.
Liva SG; Tseng YC; Dauki AM; Sovic MG; Vu T; Henderson SE; Kuo YC; Benedict JA; Zhang X; Remaily BC; Kulp SK; Campbell M; Bekaii-Saab T; Phelps MA; Chen CS; Coss CC
EMBO Mol Med; 2020 Feb; 12(2):e9910. PubMed ID: 31930715
[TBL] [Abstract][Full Text] [Related]
19. STAT3 Signalling Drives LDH Up-Regulation and Adiponectin Down-Regulation in Cachectic Adipocytes.
Mannelli M; Bartoloni B; Cantini G; Nencioni E; Magherini F; Luconi M; Modesti A; Gamberi T; Fiaschi T
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003534
[TBL] [Abstract][Full Text] [Related]
20. Sexual Dimorphism of Skeletal Muscle in a Mouse Model of Breast Cancer: A Functional and Molecular Analysis.
Rentz LE; Whetsell MA; Clayton SA; Mizener AD; Holásková I; Chapa MG; Hoblitzell EH; Eubank TD; Pistilli EE
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
